Insight Molecular Diagnostics Inc. Jul 16, 2026 Copy link Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's Business
Insight Molecular Diagnostics Inc. Jun 29, 2026 Copy link IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all Business
Insight Molecular Diagnostics Inc. Jun 22, 2026 Copy link iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant -Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Business
Insight Molecular Diagnostics Inc. Jun 16, 2026 Copy link Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to Business
Insight Molecular Diagnostics Inc. Jun 11, 2026 Copy link IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or Business
Insight Molecular Diagnostics Inc. Jun 9, 2026 Copy link iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, Business
Insight Molecular Diagnostics Inc. Feb 13, 2026 Copy link iMDx Announces $26.0 Million Registered Direct Offering NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the Business